1 week Ago By Defense World Staff
Equities researchers at StockNews.com assumed coverage on shares of Genocea Biosciences ( NASDAQ:GNCA – Get Free Report ) in a research note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance The stock has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.
61. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.
35 and a current ratio of 1.35. Genocea Biosciences has a one year low of $0.
00 and a one year high of $0.00. About Genocea Biosciences ( Get Free Report ) Read More Five stocks we like better than Genocea Biosciences How to Know Which Cryptocurrency to Buy: A Guide for Investors Quantum Opportunity: Skywater Technology’s Long-Term Potential Asset Allocation: The Key to a Successful Portfolio.
Are You Paying Attention to Yours? Nebius Group: The Rising Star in AI Infrastructure Biggest Stock Losers – Today’s Biggest Percentage Decliners MarketBeat Week in Review – 12/30 – 1/03 Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter ..
